Note: Descriptions are shown in the official language in which they were submitted.
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-1-
A
METHOD FOR PREPARING HIGH PRESSURE/HIGH SHEAR
DISPERSIONS CONTAINING PHYSIOLOGICALLY
ACTIVE INGREDIENTS
Field of the Invention
The present invention relates to methods for preparing dispersions
containing physiologically active ingredients.
Background of the Invention
Most topical preparations currently produced contain a wide variety of
physiologically active ingredients and/or aesthetic modifiers. Physiologically
active
ingredients are compounds which cause a physical change to the body following
their
application. Examples of such ingredients include alpha hydroxy acids,
antioxidants and
vitamins. Aesthetic modifiers provide the composition with a defined physical
characteristic such as, for example, the degree of moisturization, oil
content, and physical
form of the composition.
Some examples of aesthetic modifiers include silicone fluids and
derivatives, waxes, botanical (vegetable) oils, hydrocarbon-based oils, esters
and
fragrances. The performance of these ingredients is dependent upon the vehicle
used to
deliver them. These vehicles range from simple solvents, such as water or
ethanol, to
complex emulsions.
Unfortunately not all active ingredients are completely soluble or compatible
with all
vehicles. For example, oil soluble active ingredients are typically not
compatible with
water or water-based gel vehicles. As a result, many products exhibit poor
delivery of the
active ingredients, have poor tactile properties, or are thermodynamically
unstable and
result in a commercially unacceptable shelf life. Non-water based solvents can
also be
used as a vehicle for hydrophilic physiologically active materials or
aesthetic modifiers.
However, these preparations are typically not cosmetically elegant. Further,
these non-
water based solvents can cause unwanted side effects such as irritation or
damage to the
epithelial surface to which they are applied.
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-2-
High pressure high shear dispersions are finding increasing application in
cosmetic, personal care, over-the-counter (OTC), Rx, nutritional and food
products. These
systems can be mixed into a compatible base to create products with superior
performance
and aesthetic properties.
Generally, a dispersion is formed by dispersing a hydrophobic phase into a
polar, hydrophilic phase, which is principally water. However, if the material
to be
dispersed has too much polarity, or if it is solid in its native state it will
not disperse
readily and therefore is excluded from use in developing new treatment
products. This
situation is unfortunate and does not allow for the preparation of
physiologically
efficacious products using materials that can treat a particular disorder but
which are not
water dispersible in their own right.
Many physiologically active agents are unable to disperse directly into an
aqueous phase. These materials usually are simply dissolved into solvents
before they are
applied to the surface to be treated. These solvent systems are usually
hydrocarbon based
materials of varying polarity. The solvent is selected based on its ability to
dissolve the
physiologically active material of choice to treat a particular topical
disorder. These
solvent systems often are irritating, can damage the surface to which they are
applied and
are very unaesthetic. Further, if the physiologically active material is
unstable to
conventional processing methods, an alternative method of introducing the
material into a
product is necessary to maintain its beneficial properties.
To overcome the negative properties usually associated with the use of
simple aqueous or non-water based solvents, a formulator typically uses stable
dispersions
to deliver the physiologically active ingredient or aesthetic modifier to the
epithelial
surface to be treated. These dispersions form either spherical micelles of one
or more
hydrophobic liquid materials in water or spherical droplets of water in a
hydrophobic
fluid. Such dispersions are typically prepared by creating the oil phase and
water phase
then mixing the two phases together.
Specifically, the hydrophobic physiologically active ingredients or aesthetic
modifiers are dissolved in a suitable oil phase and the hydrophilic
physiologically active
ingredients or aesthetic modifiers are dissolved in water, and then the two
phases are
combined with one or more emulsifying agents which are incorporated into
either or both
the water and oil phases. These emulsifiers are surface active agents
(surfactants) whose
role is to reduce the surface tension between the oil and water phases thereby
making the
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-3-
combination of the two phases more stable. Such "emulsions" are generally
prepared by
heating the oil and water phases to elevated temperatures exceeding 70-75 C
before
combining, then slowly cooling the combined phases to ensure the development
of the
suitable crystalline and liquid crystalline structures which gives the
emulsion its
characteristic properties. These emulsions usually have a homogeneous opaque
white
appearance and a smooth or pleasant feeling upon application to the skin or
other
epithelial surface. However, the use of typical emulsion products to deliver
physiological
or aesthetic benefits has many limitations.
The presence of significant amounts of surfactant can strip material from
the lipid barrier of the skin or the lipid bilayer of epithelial cell
membranes leaving the
tissue vulnerable. Thus, the surfactants themselves can evoke an irritation or
the damaged
barrier will permit the passage of other materials that can cause irritation
or increase skin
sensitivity and allergic reactions. The literature is replete with clinical
evidence of the
damaging consequences that can occur with the use or overuse of surfactants.
For
example, Effendy I, Maibach HI, "Surfactants and experimental irritant contact
dermatitis", Contact Dermatitis 1995 Oct; 33(4);217-25 indicates that "[m]any
surfactants
elicit irritant reactions when applied to the skin, partially due to their
relative ability to
solubilize lipid membranes."; Barany E, Lindberg M, Loden M, "Biophysical
characterization of skin damage and recovery after exposure to different
surfactants",
Contact Dermatitis 1999 Feb;40(2):98-103, states that "[t]he majority of
adverse skin
reactions to personal-care products are presumed to be caused by irritant
substances, like
surfactants."
Moreover, there are limitations to conventional topical formulations. For
example, many materials with interesting aesthetic properties are not easily
produced in an
emulsion such as, for example, fluorinated compounds. Additionally, each time
the oil or
water phase is changed, the emulsifiers would need to be rebalanced. The
incorporation of
additional materials using conventional techniques can affect surface tension
adversely,
leading to the final product becoming unstable.
Many topical products formulated contain active ingredients and/or certain
aesthetic modifiers which readily become destabilized in emulsions, causing
them to
degenerate or deteriorate. For example, prolonged heating of the water and oil
phases can
thermodynamically modify the active molecule or can kinetically accelerate the
reaction of
the active with another agent in the emulsion or with air if the material is
oxygen sensitive.
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-4-
Moreover, lowering the surface tension of a topical composition generally
increases the
surface exposure of the active or sensitive aesthetic modifier to oxygen and
other
destabilizing materials. For example, when retinol is the active ingredient,
the instability
of the composition leads to lower efficacy. The instability of an unsaturated
fatty acid as
an aesthetic modifier leads to color changes and malodors in the composition.
Since the
time between manufacturing and sale of a cosmetic product is typically several
weeks, the
product is often no longer "fresh" or effective since the active ingredient
has degenerated
or deteriorated. To offset instability problems, many other materials such as
chelating
agents, antioxidants and masking agents are usually included in the
formulation.
Typical emulsions are time consuming to prepare, require heating, are
produced in multiple phases, are slow cooling, and often require high shear
conditions to
get the particle size small enough for maximum stability. Larger batches may
take from 8
to 24 hours to process and can take several days to set up. It is also very
difficult to get
excellent reproducibility of an emulsion. If any factors such as the heating,
cooling or
mixing rates are not carefully duplicated, the preparation may have different
properties
than the preceding batches of the same product. Often the difference of a
single
parameter is significant enough to cause the product to be outside the
established optimum
specifications. These batches then have to be either discarded or re-worked.
The lack of reproducibility is especially problematic when the product
contains a drug or other physiologically active ingredient. Lack of
reproducibility can
effect product performance and end user satisfaction. The lack of
reproducibility will
result in products from different batches having different aesthetic
properties which the
end user will perceive as a lack of quality and will ultimately lead to
consumer
dissatisfaction or reduced compliance.
Standard emulsion preparations also have a high cost to manufacture. This
is due to a variety of factors including the energy to heat the batch, the
specialized
equipment required to process the emulsion such as specialized pumps and
cooling/heating
equipment and the length of process ties up equipment and personnel, resulting
in
increased overhead and lost opportunity time.
Applicants have now discovered a method of forming stable dispersions of
physiologically active agents, comprising dispersing a hydrophobic phase into
a polar
hydrophilic phase which is principally water. The hydrophobic phase, which is
nonpolar
CA 02403704 2011-02-09
-5-
or low polar, is combined with the aqueous phase using high pressure high
shear conditions
to create a stable dispersion.
Applicants have discovered a method of making more efficacious formulations
than those obtained by prior art methods.
Applicants have discovered a method of forming compositions having greater
ingredient stability than prior art compositions.
Applicants have discovered a method of forming compositions which are more
cosmetically elegant and less irritating than prior art formulations.
The method of the invention also provides greater flexibility in obtaining
formulations, and substituting ingredients, and allows the formulator to
disregard HLB
rebalancing which is often a problem with the changes to formulations in the
prior art. The
method of the invention permits easier scale up to manufacturing.
The method of the invention involves reduced manufacturing costs by reducing
processing time and energy costs and lower capital investment in equipment.
The method of the invention results in much more consistent reproducibility
than prior art methods, causing less wasted batches and work-off.
Summary of the Invention
In one embodiment, the invention is directed to methods of forming a
dispersion of a nonpolar or slightly polar physiologically active agent in a
composition. The
method of the invention includes the steps of mixing a nonpolar or slightly
polar
physiologically active agent with a solvent or cosolvent, and subjecting it to
high
pressure/high shear mixing to form a stable dispersion in water, with a
particle size of from
about 50 to about 1000 nm. In other embodiments, the dispersion may have a
particle size
of from about 50 to about 500 nm.
In another embodiment, the invention is directed to a method of forming a
stable dispersion in water of a nonpolar or slightly polar physiologically
active agent, the
method comprising the steps of mixing the nonpolar or slightly polar
physiologically
CA 02403704 2011-02-09
5a
active agent with a solvent or cosolvent to form a mixture; and subjecting the
mixture to
high pressure and high shear mixing to form the stable dispersion in water,
with a particle
size of from about 50 to about 1000 nm. In this embodiment, water is added to
the mixture
prior to or during the high pressure and high shear mixing step.
Detailed Description of the Invention
A hydrophobic active ingredient or hydrophobic adjuvant of the present
invention is an active ingredient or adjuvant which has a non polar property
which makes it
essentially insoluble in water or water and polar solvent solutions.
Hydrophobic active
ingredients of the present invention include, but are not limited to,
partially and fully
hydrophobic active ingredients. For example, hydrophobic active ingredients
encompassed
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-6-
by the present invention include compounds and complexes which contain a
hydrophobic
moiety.
The topical preparation of the present invention may also include non-
hydrophobic active ingredients and non-hydrophobic adjuvants.
Suitable active agents include, but are not limited to, anti-acne agents,
antimicrobial agents, antiinflammatory agents, analgesics, antietythemal
agents,
antipruritic agents, antiedemal agents, antipsoriatic agents, antifungal
agents, skin
protectants, sunscreen agents, vitamins, antioxidants, scavengers,
antiirritants, antibacterial
agents, antiviral agents, antiaging agents, protoprotection agents, hair
growth enhancers,
hair growth inhibitors, hair removal agents, antidandruff agents, anti-
seborrheic agents,
exfoliating agents, wound healing agents, anti-ectoparacitic agents, sebum
modulators,
immunomodulators, hormones, botanicals, moisturizers, astringents, sensates,
antibiotics,
anesthetics, steroids, tissue healing substances, tissue regenerating
substances, amino
acids, peptides, minerals, ceramides, biohyaluronic acids, and any combination
of any of
the foregoing.
Preferred anti-acne agents include, but are not limited to, salicylic acid,
retinoic acid, alpha hydroxy acid, benzyl peroxide, sodium sulfacetamide,
clindamycin,
and any combination of any of the foregoing. Preferred combinations of anti-
acne agents
to be incorporated in the composition include salicylic acid, retinoic acid,
and
hydrocortisone; sodium sulfacetamide and clindamycin; salicylic acid and
clindamycin;
salicylic acid, alpha hydroxy acid, and tetrahydrozoline.
Suitable antimicrobial agents include, but are not limited to, Benzalkonium
chloride, Benzethonium chloride, Chlorhexidine gluconate, Chloroxylenol,
Clindamycin
Cloflucarban, erythromycin, Fluorosalan, Hexachlorophene, Hexylresorcinol,
Iodine
complex, Iodine tincture, Para-chloromercuriphenol, Phenylmercuric nitrate,
Thimerosal,
Vitromersol, Zyloxin, Triclocarban, Triclosan, Methyl-benzethonium chloride,
Nonyl
phenoxypoly (ethyleneoxy) ethanol-iodine, Para-chloro-meta-xylenol, Providone-
iodine
complex, Poloxamer-iodine complex, Triclorcarban, Undecoylium chloride-iodine
complex, and any combination of any of the foregoing.
Suitable antiinflammatory agents include, but are not limited to, Alidoxa,
Allantoin, Aloe Vera, Aluminum acetate, Aluminum hydroxide, Bismuth
subnitrate, Boric
acid, Calamine, Casein, Cellulose, microporous, Cholecatciferol, Cocoa butter,
Cod liver
oil, Colloidal oatmeal, Cystein hydrochloride, Dexpanthenol, Dimethicone,
Glycerin,
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-7-
Kaolin, Lanolin, Live yeast cell derivative, Mineral oil, Peruvian balsam,
Petrolatum,
Protein hydrolysate, Racemethionine, Shark liver oil, Sodium bicarbonate,
Sulfur, Talc,
Tannic acid, Topical starch, Vitamin A, Vitamin E, White petrolatum, Zinc
acetate, Zinc
carbonate, Zinc oxide, Hydrocortisone, Betamethasone, Ibuprofen, Indomethicin,
Acetyl
salicylic acid, Tacrolimus, Flucoinolone acetonide, Sodium sulfacetamide, and
any
combination of any of the foregoing.
The compositions of the invention may include a wide range of active
agents having various anti-irritation and anti-inflammatory activities.
Suitable
physiologically active agents which are too polar to be effectively dispersed
in an aqueous
(or hydrophilic) phase are the following:
Sansurf Shea butter, Sansurf DMG and Dermaguard, which have
desirable barrier properties;
Silox chamomile, sea salt, A/I liposomes, sea parsley, Sansurf Shea
Butter, InCyte Lemon Peel, MelarrestTM L, and Bisabolol SS, which act to
block signal
development;
ExCyte Hops and MelarrestTM L, which block recruitment;
ExCyte Hops, sea parsley and Heather ExCyte , which act as MMP
suppression and block neutralization agents;
MPC, Sansurf EFA, Sansurf oils, ceramides, sphingolipids and
liposomes, which act as barrier repairs;
Hyaluronic acid quaternatery compounds, MCP, HA-SOL, AMC,
Seamollient , Botanigels, Categel, moisturizations liposomes, and humectant
liposomes,
which act as humectants;
MPC, Moistureguard, vegepure, Sansurf oils and polyfix, which act as
occlusive barrier agents;
SolareaseTM OMC/1789, SolarcatTM OMC/1789 and TioSperseTM Ultra,
which act as UV abosorbers;
A/O complex, silox GT, lemon balm, ExCyte green tea, PhoCyte lemon
peel, InCyte apple and InCyte kola, which act as anti-oxidants; and
beta glucan, which enhances the immune system (acts as an immune
stimulator and enhancement).
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-8-
Suitable analgesics include, but are not limited to, diphenhydramine,
tripelennamine, benzocaine, dibucaine, lidocaine, tetracaine, camphor,
menthol, phenol,
resorcinol, matacresol, juniper tar, methylsalicylate, turpentine oil,
capsicum, methyl
nicotinate, beta-glucan, and any combination of any of the foregoing.
Suitable antierythemal agents include, but is not limited to, tetrahydrozoline
and hydrocortisone.
Suitable antipruritic agents include, but are not limited to, benadryl,
pramoxine, antihistamines, and any combination of any of the foregoing.
Suitable antiedemal agents, include, but are not limited to, pregnenalone
acetate, tanin glyrosides, and any combination of any of the foregoing.
Suitable antipsoriatic agents include, but are not limited to, caleipotriene,
coal tar, anthralin, vitamin A, and any combination of any of the foregoing.
Preferred
combinations of antipsoriatic agents include, but are not limited to,
hydrocortisone,
retinoic acid, and alpha hydroxy acid; dovonex, salicylic acid, and a
sunscreen agent;
indomethicin, salicylic acid, and urea; anthralin and salicylic acid; and
anthralin and
indomethicin. Other suitable antipsoriatic agents include, but are not limited
to,
caleipotriene, coal tar, anthralin, vitamin A, and any combination of any of
the foregoing.
Suitable antifungal agents include, but are not limited to, clioquinol,
haloprogin, miconazole nitrate, clotrimazole, metronidazole, tolnaftate,
undecylenic acid,
iodoquinol, and any combination of any of the foregoing.
Suitable skin protectants include, but are not limited to, cocoa butter,
dimethicone, petrolatum, white petrolatum, glycerin, shark liver oil,
allantoin, and any
combination of any of the foregoing.
Suitable sunscreen agents include, but are not limited to, octyl
methoxycinnamate, avobenzone, benzophenone-3, octacrylene, titanium dioxide,
zinc
oxide, and any combination of any of the foregoing.
A preferred sunscreen agent is a mixture of octylmethoxycinnamate, butyl
methoxydibenzoylmethane, cyclomethicone, one or more phospholipids and water,
and is
available as SolareaseTm from Collaborative Laboratories, Inc. of Stony Brook,
New York.
Suitable antioxidants include, but are not limited to, scavengers for lipid
free radicals and peroxyl radicals, quenching agents, and any combination of
any of the
foregoing.
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-9-
Suitable antioxidants include, but are not limited to, tocopherol, BHT, beta
carotene, vitamin A, ascorbic acid, ubiquinol, ferulic acid, azelaic acid,
thymol, catechin,
sinapic acid, EDTA, lactoferrin, rosmariquinone, hydroxytyrosole, sesamol, 2-
thioxanthine, nausin, malvin, carvacone, chalcones, glutathione isopropyl
ester, xanthine,
melanin, guanisone, lophorphyrins, 8-hydroxyxanthine, 2-thioxanthione, vitamin
B12,
plant alkaloids, catalase, quercetin, tyrosine, SOD, cysteine, methionine,
genistein,
NDGA, procyanidin, hamamelitannin, ubiquinone, trolox, licorice extract,
propyl gallate,
sinapic acid, and any combination of any of the foregoing.
Suitable vitamins include, but are not limited to, vitamin E, vitamin A
palmitate, vitamin D, vitamin F, vitamin B6, vitamin B3, vitamin B12, vitamin
C, ascorbyl
palmitate, vitamin E acetate, biotin, niacin, DL-panthenol, and any
combination of any of
the foregoing.
Suitable amino acids include, but are not limited to, glycine, serine, and any
combination of any of the foregoing.
Suitable adjuvants include, but are not limited to, aesthetic modifying
agents. The composition of the current invention includes at least one or more
aesthetic
modifying agents. An aesthetic modifying agent is a material which imports
desirable
tactile, olfactory, taste or visual properties to the surface to which it is
applied. These
materials can either be hydrophobic or hydrophillic. The aesthetic modifier
generally is a
hydrophobe. Preferably the hydrophobe is oil, wax, solid or paste. The
hydrophobic
aesthetic modifiers which are used in the present invention are dispersed into
an aqueous
phase typically by ultra high shear mixing, microfluidization or any other
method known
in the art which can produce a commercially stable dispersion that is
essentially free of
emulsifying surface active agents. The dispersions of the present invention
are produced
by mixing from about 0.1 % to about 70% hydrophobic aesthetic modifying agents
or
blends of aesthetic modifying agents with from about 30% to about 99.9%
aqueous phase
employing high pressure/high shear conditions. This produces a homogenous
fluid
dispersion which is stable for a commercially relevant period of time. The
preferred
pressure for preparing the dispersion is between about 9,000 to about 25,000
psi with a
desired shear that creates an average particle size of between about 50 to
about 1000
nanometers.
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-10-
Exemplary Embodiments of the Invention
Example 1: Essential Fatty Acid ("EFA") Complex
A first composition was formed in two beakers. The wgt % values are
calculated based on the wgt % of the resulting final composition, after the
compositions of
the beakers are combined.
In a first beaker was mixed 10 wgt % Emersol 221 oleic acid,
manufactured by Henkel Chemical Co.; 15 wgt % Emersol 315 linoleic acid,
manufactured by Henkel Chemical Co.; 5 wgt % industrene 120 liquid, linolenic
acid
enriched in coconut oil manufactured by CK Witco Chemical Co.; 0.05 wgt %
ceramide
III; 0.0001 wgt % phytospingosine, manufactured by Doosan Chemical Co.; and
0.05 wgt
% cholesterol. The composition is heated to 80 C in a water bath and stirred
until clear.
In a second beaker was mixed 54.3999 wgt % Dow Coming 345 fluid, a
cyclomethicone; 10.00 wgt% Vitamin E; 5.00 wgt % alcolec BS, a lipid supplied
by
American Lecithin; and 0.50 wgt % liquapar PE, a mixture of phenoxyethanol,
isopropylparaben and butylparaben, sold by Sutton. The composition was mixed
until
uniform at room temperature.
The first beaker was removed from heat and the contents of the first beaker
were added to the second beaker. The second beaker was cooled to room
temperature.
The composition was then filtered through Whatman 1 paper.
The resulting composition was homogeneous.
Example 2: Sansurf EFA Composition
A composition was formed in two beakers. The wgt % values were
calculated based on the basis of the wgt % of the resulting composition, after
the two
beakers were combined.
In a first beaker, 60.95 wgt% distilled water; 25.00 wgt% of the EFA
complex of Example 1; 10.0 weight% soybean oil; and 1.80 wgt% of Germazide
MPB,
were mixed.
In a second beaker, 0.25 wgt % Phosphlipon 90H (sold by American
Lecithin Co.); and 2.00 wgt% basis LP 20H are mixed.
The contents of the second beaker were added to the first beaker, and the
resulting composition was subjected to mixing with a Silverson high shear
mixer until it
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-11-
was homogeneous, and was then processed through a M110 Microfluidiser,
manufactured
by Microfluidics, Inc. of Massachusetts, at from 9,000-25,000 psi.
Example 3: SolarCatTM Composition
A first composition was formed in three beakers. The wgt % values were
'10 calculated based on the wgt % of the resulting final composition, after
the compositions of
the beakers are combined.
In a first beaker was mixed 25 wgt % Escalol 587, manufactured by Henkel
Chemical Co.; 3.0 wgt % Escalol 567, manufactured by Henkel Chemical Co. The
composition was heated to 75 C and stirred until clear.
In a second beaker was mixed 67.5 wgt % distilled water; 2.0 wgt %
Germazide MPB.
In a third beaker was mixed 2.5 wgt % Catemol S-1805, manufactured by
Phoenix Chemical. The compositions in the second and third beaker were mixed
at 75 C.
The contents of the second beaker and third beaker were added to the first
beaker, and the
resulting composition was then processed through a M110 Microfluidizer,
manufactured
by Microfluidics, Inc. of Massachusetts, at from 9,000-25,000 psi.
Example 4: Solarease OS/B3 Composition
A first composition was formed in three beakers. The wgt % values are
calculated based on the wgt % of the resulting final composition, after the
compositions of
the beakers are combined.
In a first beaker was mixed 25 wgt % Escalol 587, manufactured by Henkel
Chemical Co.; 3 wgt % Benzophenone-3, manufactured by ISP Van Dyke. The
composition was heated to approximately 80 C and stirred until clear.
In a second beaker was mixed 67.5 wgt % distilled water; 2.0 wgt %
Germazide MPB.
In a third beaker was mixed 2.5 wgt % Basis LP-20H, manufactured by
Ikeda; 0.5 wgt % Phospholipon 80H manufactured by American Lecithin. The
composition in the second beaker was subjected to mixing with a Silverson high
shear
mixer while slowly adding the composition of third beaker until it was
homogeneous. The
contents of the second beaker and third beaker were added to the first beaker,
and the
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-12-
resulting composition was then processed through a M110 Microfluidizer,
manufactured
by Microfluidics, Inc. of Massachusetts, at from 9,000-25,000 psi.
Example 5: Solarease II Composition
A first composition was formed in five beakers. The wgt % values are
calculated based on the wgt % of the resulting final composition, after the
compositions of
the beakers are combined.
In a first beaker was mixed 37.5 wgt % Escalol 557, manufactured by
Henkel Chemical Co.; 10 wgt % Parsol 1789; 1.8 wgt % Silicone Based Lemon Balm
Extract. The composition was heated to approximately 75 C and stirred until
dissolved.
The composition was then cooled to approximately 25 C.
In a second beaker was mixed 0.1 wgt % Disodium EDTA, manufactured
by Spectrum; 0.4 wgt % Potassium Sorbate USP/NF, manufactured by Tri-K; 0.01
wgt %
Phytic Acid manufactured by Sigma and 46.39 wgt % distilled water. The
composition
was then mixed in a separate vessel until all is dissolved.
In a third beaker was added 1.85 wgt % Germazide MPB. The
composition of the second and third beaker were mixed until homogenous.
In a fourth beaker was added 0.2 wgt % 99% TEA manufactured by
Kramer Chemical. The pH of this composition was then adjusted to approximately
6.50.
In a fifth beaker was mixed 1.5 wgt % of Basis LP-20H manufactured by
Ikeda and 0.25 wgt % Phospholipon 80H manufactured by American Lecithin.
The composition in the second beaker, third beaker and fourth beaker was
subjected to mixing with a Silverson high shear mixer while slowly adding the
composition of the fifth beaker until it was homogeneous. The contents of the
first beaker
was then added with the continuation of the mixing with a Silverson high shear
mixer. The
entire composition was then processed through a Ml 10 Microfluidizer,
manufactured by
Microfluidics, Inc. of Massachusetts, at from 9,000-25,000 psi.
Example 6: Sansurf OMC Composition
A first composition was formed in one beaker. The wgt % values are
calculated based on the wgt % of the resulting final composition, after the
compositions of
the beakers are combined.
CA 02403704 2002-09-17
WO 01/70197 PCT/US01/09272
-13-
In a beaker was mixed 45.90 wgt % distilled water; 28.57 wgt % Uvinul
N-539-SG, manufactured by BASF; 21.53 wgt % Escalol 557 manufactured by Henkel
Chemical Co.; 1.85 wgt % Germazide MPB; 2.00 wgt % Basis LP-20H manufactured
by
Ikeda and.25 wgt % Phospholipon 80H manufactured by American Lecithin. The
composition was subjected to mixing with a Silverson high shear mixer until it
was
homogeneous. The entire composition was then processed through a M110
Microfluidizer,
manufactured by Microfluidics, Inc. of Massachusetts, at from 9,000-25,000
psi.
Example 7: Sansurf SPF-30
A first composition was formed in three beakers. The wgt % values are
calculated based on the wgt % of the resulting final composition, after the
compositions of
the beakers are combined.
In a first beaker was mixed 25.0 wgt % Escalol 557, manufactured by
Henkel Chemical Co.; 8.0 wgt % Escalol 567, manufactured by Henkel Chemical
Co.; 6.0
wgt % Parsol 1789; and 12.5 wgt % Crodamol ISNP manufactured by Croda. The
composition was heated to approximately 75 C and stirred until dissolved. The
composition was then cooled to room temperature.
In a second beaker was mixed 44.0 wgt % distilled water; 2.0 wgt %
Germazide MPB; 0.25 wgt % Potassium Sorbate manufactured by Tri-K.
In a third beaker was mixed 2.0 wgt % Basis LP-20H manufactured by
Ikeda and 0.25 wgt % Phospholipon 80H manufactured by American Lecithin. The
composition of the second and third beaker was subjected to mixing with a
Silverson high
shear mixer while slowly adding the composition of the first beaker until it
was
homogeneous. The entire composition was then processed through a Ml 10
Microfluidizer,
manufactured by Microfluidics, Inc. of Massachusetts, at from 9,000-25,000
psi.
The various commercially available products used in the exemplary
embodiments and elsewhere in the application are described further below:
Germazide MPB is a mixture of phenoxyethanol, chlorphenesin, glycerin,
methylparaben, and benzoic acid and is available from Collaborative
Laboratories, Inc. of
East Setauket, NY.
Solarease is a mixture of octylmethoxycimiamate, butyl
methoxydibenzoylmethane, cyclomethicone, phospholipids, and water and is
available
from Collaborative Laboratories, Inc. of East Setauket, NY.
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-14-
Seamollient is a mixture of water, algae extract, chlorphenesin, propylene
glycol, sodium dehydroacetate, and phenoxyethanol and is available from
Collaborative
Laboratories, Inc. of East Setauket, NY.
Sansurf Cyclomethicone is a mixture of water, cyclopentasiloxane and
phospholipids and is available from Collaborative Laboratories, Inc. of East
Setauket, NY.
Solarease II is a mixture of octylmethoxycinnamate, butyl
methoxydibenzoylmethane, cyclomethicone, phospholipids, and water and is
available
from Collaborative Laboratories, Inc. of East Setauket, NY.
Vitamin A & E liposomes is a mixture of water, phospholipids, tocopheryl
acetate, and retinyl palmitate and is available from Collaborative
Laboratories, Inc. of
East Setauket, NY.
Sansurf DMG is a mixture of water, petrolatum, dimethicone,
perfluoropolymethylisopropylether, stearamidopropyl dimethylamine, stearic
acid, and
tocopherol acetate, and is available from Collaborative Laboratories, Inc. of
East Setauket,
NY.
SolarcatTM is a mixture of water, octyl methoxycinnamate, butyl
methoxydibenzoylmethane, cyclomethicone, stearamidopropyl dimethylamine,
stearamidopropyl dimethylamine stearate, and balm mint extract and is
available from
Collaborative Laboratories, Inc. of East Setauket, NY.
CatezomesTM OMC is a mixture of octyl methoxycinnamate and
stearamidopropyl dimethylamine stearate and is available from Collaborative
Laboratories, Inc. of East Setauket, NY.
Parsol 1789 is a butyl methoxydibenzoylmethane sold by Givaudan-Roure
Specialty Division.
Example 8: In-Vitro Sun Protection Factor ("SPF") Protocol
Background:
The SPF 290 is composed of an ultraviolet source, monochromator and a
detector. The source is a 125 W xenon lamp that emits ultraviolet (UVB) and
near
ultraviolet (UVA) radiation. This radiation then is filtered and attenuated to
accurately simulate a solar irradiance spectrum. The radiation passes through
the
sample where a portion of it is adsorbed. The light not adsorbed enters the
integrating sphere, where it is collected and then enters the monochromator.
The
CA 02403704 2002-09-17
WO 01/70197 PCT/USO1/09272
-15-
monochromator separates the light into discreet wavelength bands, which are
picked up by the detector.
The SPF 290 feeds this information into a data acquisition card, which
plugs into a computer. The computer uses this feedback to calculate SPF values
for the
sample. SPF is calculated using a series of equations. First, the
monochromatic
protection factor (MPF) is calculated as the reciprocal of transmittance. MPF
= l/T.
Transmittance in turn is the voltage feedback from the sample scan divided by
the
feedback from the reference scan. T = S/R. The value for sun protection factor
is given
by the equation
SPF = EE*B/E(E*B/MPF)
where E is the spectral irradiance of sunlight and B is the erythemal
effectiveness. The
software can calculate the standard deviation and mean of a series of MPF and
SPF
calculations.
Sample Preparation:
Cut a 5 cm x 7.5 cm piece of Transpore tape (3M Inc.) and place it on a
glass slide using double sided tape (rough surface facing up). The sunscreen-
containing
agent is distributed across the rough surface of the Transpore tape evenly at
a density of 2
ug/cm2. The only way to apply the agent is to pipette it in 1 Oul evenly
spaced drops on the
substrate. Once the sunscreen has been applied to the substrate, the material
is rubbed into
the tape with a gloved finger. The rubbing action should mimic the rubbing
action on
human skin in-vivo. Start a timer upon completion of the product rub in. Allow
the
substrate to sit for 20 minutes (dry down time).
The following table shows a product which can be formulated to make an
SPF product.
Product Percentage Used In-Vitro SPF
Sansurf OMC B-3 25 23.92
Sansurf OMC B-3 1789 30 43.06
Solarease II 20 22.1
CA 02403704 2010-07-02
-16-
Many variations of the present invention will
suggest =
themselves to those skilled in the art in light of the above, detailed
description. All such
obvious variations. are within the full intended scope of the appended claims.
